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Rabbit hemorrhagic disease virus (RHDV) causes lethal fulminant hepatitis closely resembling acute liver
failure (ALF) in humans. In this study, we investigated whether cardiotrophin-1 (CT-1), a cytokine with
hepatoprotective properties, could attenuate liver damage and prolong survival in virus-induced ALF. Twenty-
four rabbits were infected with 2  104 hemagglutination units of RHDV. Twelve received five doses of CT-1
(100 g/kg) starting at 12 h postinfection (hpi) (the first three doses every 6 h and then two additional doses
at 48 and 72 hpi), while the rest received saline. The animals were analyzed for survival, serum biochemistry,
and viral load. Another cohort (n  22) was infected and treated similarly, but animals were sacrificed at 30
and 36 hpi to analyze liver histology, viral load, and the expression of factors implicated in liver damage and
repair. All infected rabbits that received saline died by 60 hpi, while 67% of the CT-1-treated animals survived
until the end of the study. Treated animals showed improved liver function and histology, while the viral loads
were similar. In the livers of CT-1-treated rabbits we observed reduction of oxidative stress, diminished
PARP1/2 and JNK activation, and decreased inflammatory reaction, as reflected by reduced expression of
tumor necrosis factor alpha, interleukin-1, Toll-like receptor 4, VCAM-1, and MMP-9. In addition, CT-1-
treated rabbits exhibited marked upregulation of TIMP-1 and increased expression of cytoprotective and
proregenerative growth factors, including platelet-derived growth factor B, epidermal growth factor, platelet-
derived growth factor receptor , and c-Met. In conclusion, in a lethal form of acute viral hepatitis, CT-1
increases animal survival by attenuating inflammation and activating cytoprotective mechanisms, thus rep-
resenting a promising therapy for ALF of viral origin.
Acute liver failure (ALF) arises as a result of extensive
hepatocellular damage that exceeds the liver’s capacity to re-
generate. Depending on the interval between the onset of
jaundice and that of encephalopathy, ALF can be categorized
into hyperacute (less than 1 week), acute (between 1 and 4
weeks) and subacute (more than 4 weeks). Etiologic factors
include viral infections, drugs, biological toxins, metabolic dis-
orders, and ischemia, but it is not unusual for this syndrome to
arise without any known causative agent (22).
ALF is one of the most challenging human conditions re-
quiring critical care. Therapy is merely supportive and oriented
to the correction of complications. Survival is poor and liver
transplantation is the only definitive treatment for patients
with severe ALF. However, the indication for liver transplan-
tation relies on prognostic assessment, and this lacks accuracy.
In transplanted patients mortality is about 10%, but ca. 30% of
patients with ALF die without having access to transplantation
(24). Thus, novel medical treatments for this condition are
urgently needed. With the exception of N-acetylcysteine, which
can prevent glutathione depletion in paracetamol overdose
(11), pathogenic therapies able to attenuate liver cell necrosis
and stimulate regeneration are lacking.
Viral infections due to hepatitis B virus, hepatitis A virus,
and hepatitis E virus are common causes of ALF, mainly in
particular geographical areas of the world (22). The mecha-
nisms responsible for liver injury in acute severe viral hepatitis
leading to ALF are complex and include the virus cytopathic
effect, the damage induced by a vigorous inflammatory re-
sponse, and the cytotoxicity of immune effectors. Most animal
models of ALF, including the administration of hepatotoxins,
the injection of substances that activate immune cells (e.g.,
concanavalin A [ConA]), and the infusion of molecules that
directly promote apoptosis of hepatocytes (e.g., Fas ligand), do
not reproduce the complexity of cell-damaging mechanisms
activated in patients with severe acute viral hepatitis. An im-
portant difficulty for testing innovative therapeutic approaches
for ALF of viral origin is the lack of appropriate animal models
that develop massive hepatocellular necrosis as result of viral
infection.
Recently, it has been shown that the rabbit hemorrhagic
disease virus (RHDV), a member of the Caliciviridae family,
causes a life-threatening form of viral hepatitis that recapitu-
lates many of the features of human ALF, including a tendency
to bleeding, encephalopathy, and intracranial hypertension (7,
31). More than 90% of infected adult rabbits die as result of
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massive liver damage within 3 days. Since RHDV infection
constitutes a highly reproducible model of virus-induced ALF,
it offers a valuable scenario to test the therapeutic potential of
hepatoprotective therapies in this condition.
Cardiotrophin-1 (CT-1) is a member of the interleukin-6
(IL-6) family of cytokines, which is endowed with potent cyto-
protective properties. CT-1 activates different cell survival
pathways, including STAT-3, AKT, and ERK1/2, and induces
the expression of antiapoptotic factors (4, 15). It has been
reported that CT-1 defends the liver against ConA challenge
and ischemia/reperfusion damage (4, 15). However, it is not
known whether this cytokine displays therapeutic effects in
acute severe viral hepatitis. Therefore, the aim of the present
study was to investigate whether CT-1 is able to attenuate liver
damage and improve survival in a relevant model of virus-
induced ALF.
MATERIALS AND METHODS
Animals. Nine-week-old New Zealand White rabbits were kept in the animal
facility of the University of Leon with 12-h light cycle at 21 to 22°C and 50%
relative humidity. They were given water and standard dry rabbit food ad libitum.
Animals received care according to the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health, 1985). The study protocols were reviewed
and approved by the University of Leon Animal Care Committee.
Experimental Procedure. For survival studies, 24 rabbits (cohort 1) were
injected intramuscularly with 2  104 hemagglutination units of a RHDV isolate
(32). At 12, 18, 24, 48, and 72 h postinfection (hpi), 12 animals received an
intravenous injection of rat CT-1 (100 g/kg [body weight] dissolved into 3 ml of
saline; Dro Biosystems, San Sebastian, Spain), and the other 12 animals received
the same volume of vehicle (saline). Animals from both groups were left to die
spontaneously, and all of the surviving rabbits from the CT-1-treated group were
sacrificed at 7 days postinfection.
To investigate the molecular changes taking place in liver tissue in the infected
untreated and treated groups, we used another cohort of animals (cohort 2, n 
22) which were infected and treated with saline or CT-1 as described above.
Surviving animals from this cohort were sacrificed at 30 hpi (four from the saline
group and six treated with CT-1) or 36 hpi (five from the saline group and six that
received CT-1). A group of noninfected rabbits (n  6) of the same age and
gender were used as healthy controls and were sacrificed at the time of the study.
In addition, a group of six noninfected normal rabbits received three injections
of CT-1 (100 g/kg [body weight]) every 6 h and were sacrificed 6 h after the last
injection in order to investigate the effects of CT-1 in normal rabbit liver.
Cell culture. SIRC rabbit corneal cells (ATCC CL-60) were grown in Dul-
becco minimum essential medium (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100
g/ml). SIRC cells were treated with 25 ng of rat CT-1/ml and were collected at
different time points.
Biochemical and virological analysis. Blood samples from cohort 1 were
collected from the marginal ear vein of surviving animals in heparin tubes at 12,
18, 24, 36, and 48 hpi, and at 7 days postinfection for determination of aspartate
aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, and glu-
cose. The RHDV viral load was measured in plasma and in liver extract by
quantitative real-time PCR (for primers, see Table S1 in the supplemental
material). The copy number was determined by extrapolation from the cycle
threshold of each sample on a standard curve of known concentration. The
standard was generated by insertion of the RHDV amplicon in a pCR2.1-TOPO
vector (TOPO TA cloning kit; Invitrogen).
Histological analysis. Liver samples from surviving animals at 7 days postin-
fection (cohort 1), and animals sacrificed at 30 hpi (cohort 2) were stained with
hematoxylin and eosin for histological examination. Immunohistochemical anal-
ysis of antigen Ki-67 (MM1 clone; Novocastra, Newcastle, United Kingdom) as
a marker of cellular proliferation was carried out in liver specimens. Liver
histology was evaluated by an experienced veterinary pathologist and semiquan-
titative assessment of different histological parameters was performed.
Western blot analysis. Western blot analyses in liver tissue homogenates were
performed as described previously (7) using the following antibodies: anti-poly-
(ADP-ribose)polymerase-1 (PARP1/2), anti-HGF, anti-PDGFR, and anti-
Lamin-B (Santa Cruz Biotechnology, Santa Cruz, CA), horseradish peroxidase-
conjugated antibody (Dako, Glostrup, Denmark), anti--actin (Sigma), and anti-
JNK and anti-phospho-JNKThr183/Tyr185 (Cell Signaling, Danvers, MA). The
density of the specific bands was quantified with an imaging densitometer (Scion
Image, Frederick, MD).
RNA extraction and reverse transcription-PCR. Total RNA extraction from
liver tissue and cDNA synthesis were performed as described previously (4).
cDNA was amplified using TaqMan Universal PCR MasterMix (primers and
probes in Table S2 in the supplemental material) or QuantiTect SYBR green
PCR master mix (see primers in Table S1 in the supplemental material) (Applied
Biosystems, Foster City, CA). Relative changes in gene expression levels were
determined by using the 2CT method as described previously (19). The results
were normalized according to GAPDH (glyceraldehyde-3-phosphate dehydro-
genase).
Oxidative stress parameters. Oxidized and reduced glutathione analysis was
performed fluorimetrically by the method of Hissin and Hilf (14). Lipid peroxi-
dation products were quantified in 250 mg of tissue extract by determining
thiobarbituric acid reactive substances (TBARS) (34).
Statistical analysis. Results are expressed as mean values  the standard
errors of the mean. Statistical analyses were performed using nonparametric
(Kruskal-Wallis and Mann-Whitney U) tests. All P values were two tailed and
considered significant if 0.05. Kaplan-Meier plots and log-rank tests were used
to analyze survival. Values were analyzed with the statistical package Statistica
7.0 (Statsoft, Inc., Tulsa, OK).
RESULTS
Treatment with CT-1 reduces liver damage and improves
survival in RHDV-induced acute liver failure. Twelve hours
after intramuscular administration of 2  104 hemagglutina-
tion units of RHDV, the infected rabbits started to show pros-
tration, side recumbency, respiratory agitation, and tachycar-
dia. In infected animals given saline, these symptoms were
followed by neurological disturbances (convulsions, ataxia, and
posterior paralysis), which rapidly progressed to coma and
death. Eight rabbits from this group died before 48 hpi, and no
animal survived at 60 hpi. In sharp contrast, 67% (n  8) of
animals that received CT-1 survived until they were sacrificed
at the end of the study period (day 7 postinfection) (Fig. 1A).
Serum transaminases (which reflect the extent of hepatocellu-
lar death) experienced a striking elevation after 24 hpi, but the
values were significantly less increased in RHDV-infected ani-
mals treated with CT-1 than in those receiving saline (Fig. 1B and
C). Similarly, serum bilirubin levels (whose elevation results from
the liver failure to transport bilirubin to bile) increased markedly
at 36 and 48 hpi in the two groups, but the rise was significantly
lower in CT-1-treated animals (Fig. 1D). In CT-1-treated animals
that survived, the biochemical parameters approached normal
values at day 7 postinfection (Fig. 1B to D).
In ALF, plasma hypoglycemia develops because of impaired
gluconeogenesis and reduced insulin clearance (23, 28). In un-
treated infected rabbits, plasma glucose dropped profoundly as
result of liver failure, while it was maintained at significantly
higher values in animals which received CT-1 therapy (Fig. 1E).
Effect of CT-1 therapy on liver histopathology. At 30 hpi the
livers of untreated RHDV-infected rabbits exhibited a severe
acute inflammatory reaction with extensive areas of hepatocel-
lular necrosis, intense hyperemia, edema and hemorrhage, and
heterophil infiltration (rabbit heterophil leukocytes are equiv-
alent to human neutrophils). Portal tracts showed moderate
cell infiltration. Non-necrotic hepatocytes manifested cytoplas-
mic swelling and vacuolation occurring mainly in the cen-
trolobular area. In infected rabbits given CT-1 therapy, the
livers showed lobular inflammation with heterophil infiltration,
but necrotic areas were markedly reduced compared to those
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of infected controls, and cell swelling and vacuolation were
almost absent (Fig. 2). In normal noninfected rabbits receiving
a similar dose of CT-1, the liver histology (and routine bio-
chemical data) was comparable to that of normal rabbits given
saline (Fig. 2A and B and data not shown). At day 7 postin-
fection, the livers of the surviving CT-1-treated animals
showed inflammatory infiltrate in portal tracts and moderate
portal and periportal fibrosis, together with the presence of
some inflammatory foci in the lobule composed of mononu-
clear cells and heterophils (Fig. 2E). In these animals, numer-
ous Ki-67-positive nuclei were present in hepatocytes, a finding
consistent with the activation of a vigorous postnecrotic regen-
erative process (Fig. 2F).
CT-1 has no influence on RHDV replication. To determine
whether improved survival in CT-1 treated rabbits was related
to inhibition of viral replication, RHDV viral load was quan-
tified in plasma and liver tissue from CT-1-treated and un-
treated animals. We found that RHDV-RNA plasma levels
during the course of the infection were similar in all RHDV-
infected rabbits irrespectively of the treatment they received
(saline or CT-1) (Fig. 3A). Moreover, the viral load in liver
tissue at 30 and 36 hpi was comparable in the two groups (Fig.
FIG. 1. Survival and liver function in RHDV-infected animals treated with saline or CT-1. (A) Percentage of surviving animals after RHDV
infection that were treated with CT-1 or saline. Alanine aminotransferase (ALT) (B), aspartate aminotransferase (AST) (C), bilirubin (D), and
glucose (E) plasma levels in animals after RHDV infection untreated or CT-1 treated (cohort 1) were determined. Shaded areas represent the
range of normal values (means  standard deviations). #, P  0.05; ##, P  0.01 (CT-1-treated RHDV-infected rabbits versus untreated
RHDV-infected animals).
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3B). Plasma RHDV-RNA levels reached values of 108 ge-
nomes/ml in both treated and untreated rabbits at 48 hpi, when
mortality was very high in the untreated group. Virus titers
declined subsequently in the surviving CT-1-treated animals to
reach low levels (103 viral genomes/ml) by day 7 when the
animals were sacrificed. Thus, the survival benefit afforded by
CT-1 appears to be due to factors other than interference in
RHDV replication.
CT-1 attenuates oxidative stress and the inflammatory re-
action in the liver in rabbits with RHDV-induced acute liver
failure. As noted above, RHDV-induced ALF is characterized
by a severe acute inflammatory reaction in the liver. High
levels of proinflammatory mediators ignite the production of
reactive oxygen species (ROS) leading to persistent JNK phos-
phorylation, PARP activation, and necrapoptosis (17). We
evaluated the extent of oxidative stress by determining the
oxidized/reduced glutathione (GSSG/GSH) ratio and the lev-
els of TBARS (as a reflection of lipid peroxidation) in liver
tissue from untreated and CT-1-treated infected animals sac-
rificed at 30 and 36 hpi. At both time points, GSSG/GSH ratio
and TBARS values were significantly increased in RHDV-
infected rabbits given saline compared to healthy livers. In
contrast, in RHDV-infected animals treated with CT-1, both
the TBARS values and the GSSG/GSH ratio were significantly
lower than in animals given saline and were similar to those of
healthy controls (Fig. 4A and B). Interestingly, JNK phosphor-
ylation was prominent at 30 hpi in livers from RHDV-infected
rabbits but was markedly attenuated in four of six animals
treated with CT-1 (Fig. 4C). In parallel with these findings,
PARP1/2 cleavage was prominent at both 30 and 36 hpi in the
group of infected rabbits given saline but inconspicuous in four
of six animals treated with CT-1 (Fig. 4C and data not shown).
Thus, RHDV infection causes strong oxidative stress, JNK
activation, PARP1/2 cleavage, and massive necrapoptosis. The
FIG. 2. Liver histology from normal rabbits treated or not treated with CT-1 and from RHDV-infected animals treated with saline or CT-1.
Hematoxylin and eosin staining of liver samples from a healthy rabbit (A), a normal rabbit treated with CT-1 (see Materials and Methods) (B),
an RHDV-infected rabbit treated with saline at 30 hpi (C), an RHDV-infected rabbit treated with CT-1 at 30 hpi (D), and an RHDV-infected
rabbit treated with CT-1 that survived at day 7 postinfection (E) and Ki-67 staining of RHDV-infected rabbit treated with CT-1 that survived at
day 7 postinfection (F) was performed. Cytoplasmic swelling and vacuolation (csv) and extensive areas of hepatocellular necrosis (hn) are seen in
panel C, while these changes are markedly attenuated in panel D. Residual foci of inflammation and increased numbers of Ki67-positive nuclei
(in brown) are seen in panels E and F. Images show representative microphotographs from six animals in panel A, six animals in panel B, four
animals in panel C, six animals in panel D, and eight animals in panels E and F.
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surviving benefit afforded by CT-1 therapy is associated with
marked attenuation of this chain of events.
Proinflammatory cytokines have been shown to play a key
role in acute liver injury of various etiologies (2, 35). We found
that the mRNA levels of IL-1, IL-6, and tumor necrosis factor
alpha (TNF-	) were strongly elevated in RHDV-infected livers
compared to healthy controls and that CT-1 therapy resulted in
a significant reduction in the expression of all of these mole-
cules (Fig. 5A, B, and C). Importantly, liver expression of
endogenous CT-1 dropped markedly in all infected animals
(possibly as a result of the profound hepatocellular damage)
without differences between those that were treated with saline
or CT-1 (data not shown).
Toll-like receptor 4 (TLR4) is also an important trigger of
the inflammatory reaction. TLR4 is activated by both patho-
gen-associated molecular patterns and endogenous ligands de-
rived from extracellular matrix (ECM) degradation and necro/
apoptotic cells (30). Marked TLR4 upregulation has been
described in different viral infections (13, 39). Activation of
TLR4 may ignite cascades of proinflammatory cytokines, thus
FIG. 3. RHDV viral load in RHDV-infected rabbits treated with saline or CT-1. RHDV viral load in plasma from animals of cohort 1 (A) and
in liver tissue from animals of cohort 2 (B). Rabbits were RHDV infected and treated with CT-1 (RHDVCT-1) or with saline (RHDV).
FIG. 4. Oxidative stress, JNK, and PARP1/2 in the livers of normal rabbits and RHDV-infected animals treated with saline or CT-1. TBARS
(A) and GSSG/GSH ratio (B) are shown. (C) Western blot analysis of JNK activation and PARP1/2 cleavage in liver tissue from noninfected
(control), RHDV-infected animals treated with CT-1 (RHDVCT-1) or with saline (RHDV). #, P  0.05; ##, P  0.01 (CT-1-treated
RHDV-infected rabbits versus RHDV-infected animals that received saline). *, P  0.05; **, P  0.01 (RHDV-infected animals versus
noninfected controls).
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aggravating hepatocellular damage in severe forms of acute
liver disease (10). Accordingly, gene deletion of TLR4 has
been shown to palliate liver injury in experimental models of
acute liver damage (38). We found that CT-1 therapy signifi-
cantly dampened the elevation of TLR4 expression that oc-
curred in livers from RHDV-infected rabbits (Fig. 5D). A
similar effect was observed with respect VCAM-1 expression.
This membrane molecule is involved in transendothelial mi-
FIG. 5. Expression of inflammatory markers in livers from normal rabbits and RHDV-infected animals treated with saline or CT-1. mRNA
expression of IL-1 (A), IL-6 (B), TNF-	 (C), TLR4 (D), VCAM-1 (E), COX-2 (F), MMP-9 (G), and TIMP-1 (H) in liver tissue from uninfected rabbits
(control) and RHDV-infected animals treated with saline (RHDV) or with CT-1 (RHDVCT-1). #, P  0.05; ##, P  0.01 (CT-1-treated
RHDV-infected rabbits versus RHDV-infected rabbits given saline). *, P  0.05; **, P  0.01 (RHDV-infected animals versus noninfected controls).
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gration of leukocytes and ROS production (21). We found that
it is highly induced in RHDV infection and that CT-1 therapy
strongly inhibited its expression (Fig. 5E). COX-2 is also a key
driver of inflammation whose expression is enhanced by pro-
inflammatory cytokines (18). COX-2 was markedly upregu-
lated in the livers of rabbits with RHDV infection, and this
effect was significantly reduced by CT-1 (Fig. 5F).
Activation of matrix metalloproteinases (MMPs), particu-
larly MMP-9, is a critical event in the development of experi-
mental ALF. By degrading ECM, MMPs facilitate leukocyte
influx, collapse of sinusoids, and parenchymal hemorrhage.
MMP inhibitors or genetic deletion of MMP-9 defend mice
against ALF elicited by LPS/D-()-galactosamine or TNF-	/
D-()-galactosamine (33, 37). TIMP-1 is an endogenous inhib-
itor of MMPs, but it also exerts potent cell survival and growth-
promoting activities independently of its MMPs blocking
effects (9, 12). In the livers of RHDV-infected animals, we
observed a vigorous overexpression of MMP-9 without
changes in TIMP-1 mRNA values. Strikingly, in the liver of
RHDV-infected rabbits which received CT-1, MMP-9 upregu-
lation was considerably attenuated, whereas TIMP-1 was
highly hyperexpressed (Fig. 5G and H). TIMP-1 appears to be
a target gene of CT-1. In fact, we observed that incubation of
rabbit corneal cells with this cytokine elicited a striking up-
regulation of TIMP-1 gene expression (Fig. 6A). Confirming
these data, we found that normal noninfected rabbits treated
with CT-1 (three injections of 100 g/kg separated by 6 h) and
sacrificed 6 h after the last dose showed a robust elevation of
TIMP-1 mRNA in liver tissue (Fig. 6B).
CT-1 stimulates cytoprotective and proregenerative factors
in RHDV-infected livers. Tissue defense against noxious insults
is orchestrated by a diversity of growth factors and cytokines,
including HGF (8), EGFR ligands (16), PDGF (29), and CT-1
(4), among others. In the livers of RHDV-infected rabbits
given saline, we found a marked decrease of HGF at 36 hpi and
of its receptor c-Met at both 30 and 36 hpi. The infected
rabbits treated with CT-1 exhibited higher hepatic expression
of HGF at 36 hpi and of c-Met at 30 and 36 hpi than the
infected animals which received saline (Fig. 7D and E). Also,
the PDGF-B gene expression and protein levels of PDGFR
in liver tissue dropped intensely at 30 and 36 hpi in control
RHDV-infected rabbits while those treated with CT-1 showed
significantly higher values of both PDGF-B and its receptor at
both time points (Fig. 7A, C, and E). Furthermore, CT-1
therapy prevented the profound decline of hepatic EGF
mRNA levels taking place in RHDV infection, with values at
36 hpi that were significantly higher in rabbits treated with
CT-1 than in RHDV-infected rabbits given saline (Fig. 7B).
DISCUSSION
RHDV infection is a unique model that closely reproduces
the histopathological, biochemical, and clinical manifestations
of human fulminant viral hepatitis (31). Therefore, we selected
RHDV-induced ALF to determine whether CT-1 might rep-
resent a potential therapy for this condition and to define the
responsible mechanisms.
Previously, we reported that CT-1 is a potent hepatoprotec-
tive cytokine with the ability to attenuate ConA hepatitis, Fas-
induced hepatocellular damage, and ischemia/reperfusion in-
jury (4, 15, 20). However, its role in fulminant viral hepatitis
has never been tested. In the present study, RHDV-infected
animals received five doses of CT-1, the first one at 12 hpi. This
time point was selected because of the rapid evolution of
RHDV infection. Later in the course of the disease, rabbits left
untreated were so ill and prostrated that it was technically
difficult to administer intravenous injections.
Notably, while 100% of rabbits with RHDV died within 60 h,
CT-1 treatment allowed 67% survival at day 7 postinfection,
which was the end of the study period (unpublished observa-
tions from our group indicate that, after this time point, the
animals that were not sacrificed survived normally). This re-
markable therapeutic efficacy could not be ascribed to any
antiviral effect of the cytokine since the plasma viral load was
similar in treated and untreated animals up to 48 hpi, a time
point where mortality was much higher in untreated than in
CT-1-treated rabbits. Also, RHDV-RNA abundance in liver
tissue was comparable at 30 and 36 hpi in the two groups of
animals. Our data indicate that the beneficial effect of CT-1
appears to be due to the mitigation of inflammation, the re-
duction of oxidative stress, and the activation of endogenous
cytoprotective and growth-promoting mechanisms. Indeed,
CT-1-treated animals exhibited a significant reduction in the
expression of key drivers of inflammation, such as TNF-	,
IL-1, COX-2, and TLR4, which are known to be relevant
mediators of tissue damage in the inflamed liver (2, 10, 18). On
the other hand, in the treated rabbits the alleviation of the
inflammatory reaction within the liver was accompanied by a
significant decrease in oxidative stress as reflected by de-
creased levels of lipid peroxidation products and reduced
GSSG/GSH ratio. The decrement of oxidative stress might be
a consequence of the anti-inflammatory properties of CT-1,
but it could also be due to the reported ability of this cytokine
to stimulate antioxidant genes (15). Persisting production of
ROS in the inflamed tissues causes prolonged JNK phosphor-
ylation, leading to PARP1/2 activation and necrapoptosis (17).
This chain of events appears to be inhibited by CT-1 adminis-
tration. Supporting this view, we found that JNK activation and
PARP1/2 cleavage were readily detectable in liver tissue at 30
hpi in untreated RHDV-infected rabbits but not in four out of
six CT-1-treated infected animals.
FIG. 6. Induction of TIMP-1 mRNA expression after treatment
with CT-1. (A) Kinetics of TIMP-1 mRNA expression in SIRC rabbit
corneal cells treated with 25 ng of CT-1/ml. (B) Expression of TIMP-1
mRNA in liver tissue from normal rabbits that received treatment with
CT-1 or were left untreated (control). *, P  0.05; **, P  0.01
(CT-1-treated versus untreated rabbits).
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In addition to these effects, we observed that CT-1 therapy
prevented the intense MMP-9 upregulation that occurred in
RHDV infection. Recently, it has been found that IL-1-medi-
ated MMP-9 induction plays an essential pathogenic role in
models of ALF by promoting degradation of ECM, which
leads to apoptosis of hepatocytes and parenchymal hemor-
rhage (37). In addition, the release of ECM-derived peptides
triggers the influx and activation of polymorphs which enhance
tissue damage (36). Importantly, CT-1 not only prevented
MMP-9 overexpression but also provoked a dramatic increase
of TIMP-1 mRNA levels. TIMP-1 appears to be a target gene
of CT-1, since its expression is readily stimulated in the liver of
normal rabbits treated with this cytokine, and it is also en-
hanced in cultured rabbit corneal cells incubated in the pres-
ence of CT-1. TIMP-1 is an inhibitor of MMPs but also acts as
a potent antiapoptotic and proregenerative molecule (9, 12).
In fact, production of TIMP-1 by neoplastic cells facilitates
tumor progression and resistance to chemotherapy (5). Thus,
inhibition of MMP-9 expression, together with the upregula-
tion of TIMP-1, may constitute key mechanisms by which CT-1
attenuates liver injury in RHDV infection.
In addition to the effects described above, CT-1 therapy
triggered the expression in the inflamed liver of growth factors
and growth factors receptors, including PDGF-B and
PDGFR. Increased levels of these molecules have been well
documented in acute liver damage (25). PDGF-B is endowed
with cytoprotective activity and promotes hepatocyte prolifer-
ation (3). In patients with ALF it has been shown that PDGF-B
plasma levels correlate positively with survival (29), suggesting
that upregulation of this growth factor may foster recovery. We
FIG. 7. Expression of growth factors and growth factor receptors in the liver from normal rabbits and from RHDV-infected animals treated
with saline or CT-1. mRNA expression of PDGF-B (A), EGF (B), PDGFR (C), and c-Met (D) was examined. (E) Representative Western blots
of HGF and PDGFR normalized with -actin. The densitometric analysis corresponds to data from all cohort 2 animals. Analyses were
performed in liver tissue from uninfected rabbits (control) and RHDV-infected rabbits treated with CT-1 (RHDVCT-1) or saline (RHDV). #,
P  0.05; ##, P  0.01 (CT-1-treated RHDV-infected rabbits versus untreated RHDV-infected animals). *, P  0.05; **, P  0.01 (RHDV-
infected animals versus noninfected controls).
VOL. 85, 2011 CT-1 IN FULMINANT VIRAL HEPATITIS 13131
 o
n
 August 6, 2012 by Universidad de Navarra
http://jvi.asm.org/
D
ow
nloaded from
 
also found that CT-1 induced the expression of EGF and
c-Met. The latter is the receptor for HGF, a potent hepato-
protective factor (8) whose protein levels are increased in the
liver of CT-1-treated rabbits. EGF, on the other hand, exerts
antiapoptotic effects and acts as a potent hepatomitogen (16).
Thus, it is likely that upregulation of all of these molecules
contributes to diminish hepatocellular damage and to stimu-
late regeneration following severe acute liver injury.
It has been shown that, in addition to hepatocytes, RHDV
can also infect endothelial cells and intravascular macrophages
by promoting the activation and apoptosis of these cells, which
may play a pathogenic role in RHDV-induced ALF (1, 27). It
has been reported that CT-1 reduces macrophage activation
(6) and exerts a protective role on endothelial cells (26). These
effects on nonparenchymal cells might also contribute to the
attenuation of liver damage observed in the infected animals
treated with CT-1.
To summarize, we have shown that, in rabbits with lethal
viral hepatitis, CT-1 therapy was able to diminish liver necrosis
and to improve survival dramatically. This beneficial effect was
associated with attenuation of inflammation, reduction of pro-
oxidant injury, downregulation of MMP-9, upregulation of
TIMP-1, and overexpression of several growth factors and re-
ceptors. Since CT-1 does not affect viral replication, it seems
that modulation of innate immunity and inflammation may
significantly reduce hepatocellular damage in acute severe viral
hepatitis. In conclusion, our data point to CT-1 as a molecule
of potential therapeutic value for patients with ALF of viral
origin.
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